Edgewise Therapeutics (EWTX) Enterprise Value (2020 - 2026)

Edgewise Therapeutics has disclosed Enterprise Value across 7 years of filings, most recently posting -$499.6 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$499.6 million, down 14.48% year-over-year; the trailing twelve-month figure through Mar 2026 was -$499.6 million (down 14.48% YoY), and the FY2025 annual result was -$61.1 million, down 46.76% from the prior year.
• Enterprise Value came in at -$499.6 million for Q1 2026 at Edgewise Therapeutics, down from -$61.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$22.0 million in Q4 2022 to a low of -$594.0 million in Q2 2025.
• The 5-year median for Enterprise Value is -$248.4 million (2022), against an average of -$229.7 million.
• Across the five-year window, Enterprise Value jumped 90.77% in 2024 and slumped 1341.98% in 2025, its largest moves.
• Edgewise Therapeutics' Enterprise Value stood at -$22.0 million in 2022, then plunged by 291.47% to -$86.1 million in 2023, then jumped by 51.61% to -$41.7 million in 2024, then sank by 46.76% to -$61.1 million in 2025, then plunged by 717.03% to -$499.6 million in 2026.
• The last three Enterprise Value figures came in at -$499.6 million (Q1 2026), -$61.1 million (Q4 2025), and -$46.0 million (Q3 2025), per Business Quant data.